An Examination of the Mechanism
Pretorius & co. (I think you cited them in another post) have also hypothesized that diabetes pre-disposes for clotting because of baseline high inflammation / amyloid microclots. This one from before they started adding spike - https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7670290/
"In addition, individuals with T2DM are more prone to develop microclots, due to an increased presence of circulating inflammatory biomarkers that cause hypercoagulability. T2DM patients are therefore predisposed due to their condition. When these individuals then contract SARS-CoV-2, they are already prone to hypercoagulation. This hyperocuagulable predisposition, explains why individuals with T2DM are more prone to develop severe hypercoagulability when diagnosed with COVID-19."
The same would probably hold true for repeat doses, as in prime+boost hypercoagulation, though circulating antibodies seem to camouflage spike in plasma based on Röltgen, et al. (lower detection in plasma after second dose - https://www.cell.com/cell/fulltext/S0092-8674(22)00076-9) so maybe this reduces the impact.
I love reading your work…for 2 years now! Especially on your new substack, Twitter is a bit tedious. Thank you Walter Xxxxxxxxxxxxxxx 💖👩🏼🌾🎨🦋